Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS: A total of 29 patients with metastatic biliary tract cancer received GEMFUFOL regimen as the first- line treatment. The mean follow-up was 22.1 months (95%CI, 12.5-31.8). One patient (3.4%) achieved complete response, 5 (17.2%) had partial response, and 4 (13.8%) had stable disease. The median progression-free survival was 3.3 months (95%CI, 2.9-3.7), and the median overall survival was 8.8 months (95%CI, 3.5-14). The 1-year and 2-year survival rates were 58.6% and 30%, respectively. Grade 3 and 4 toxicity included neutropenia in 4 patients (13.7%), thrombocytopenia in 2 (6.8%), anemia in 2 (6.8%), and alopecia in 1 (3.4%). Two patients (6.8%) developed febrile neutropenia. A dose reduction was achieved in 8 patients (27.6%) while 5 patients had extended-interval dosage (17.2%) for toxicity. CONCLUSIONS:
|
Authors | Olcun Umit Unal, Ilhan Oztop, Ilkay Tugba Unek, Ahmet Ugur Yilmaz |
Journal | Asian Pacific journal of cancer prevention : APJCP
(Asian Pac J Cancer Prev)
Vol. 14
Issue 9
Pg. 5263-7
( 2013)
ISSN: 2476-762X [Electronic] Thailand |
PMID | 24175811
(Publication Type: Journal Article)
|
Chemical References |
- Deoxycytidine
- Leucovorin
- Fluorouracil
- Gemcitabine
|
Topics |
- Adenocarcinoma
(drug therapy, mortality, secondary)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biliary Tract Neoplasms
(drug therapy, mortality, pathology)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Female
- Fluorouracil
(administration & dosage)
- Follow-Up Studies
- Humans
- Infusions, Intravenous
- Leucovorin
(administration & dosage)
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Staging
- Prognosis
- Retrospective Studies
- Survival Rate
- Gemcitabine
|